Skip to main content

Table 1 Demographics and estimates of kidney function in the CRISP population at baseline

From: Relationship between caffeine intake and autosomal dominant polycystic kidney disease progression: a retrospective analysis using the CRISP cohort

Characteristic

Total N = 239

Caffeine Consumer N = 188 (79)

Non-Caffeine Consumer N = 51 (21)

P-value for difference between caffeine and non-caffeine consumers

Age*, years

Mean (± sd)

32.3 ± 8.7

32.3 ± 8.9

32.4 ± 9.0

0.935

Median (IQR)

33.8 (25.1, 39.7)

33.6 (25.0, 39.7)

34.2 (16.0, 39.4)

Race (White), n (%)

207 (87)

167 (89)

40 (78)

0.089

Sex (Male), n (%)

96 (40)

78 (41)

18 (35)

0.523

BMI*, kg/m2

Mean (± sd)

25.91 ± 5.3

26.1 ± 5.5

25.3 ± 4.3

0.564

Median (IQR)

25.17 (21.98, 28.64)

25.24 (22.04, 29.03)

25.07 (22.06, 27.64)

Smoking, n (%)

40 (17)

36 (19)

4 (8)

0.088

Hypertension, n (%)

146 (61)

113 (60)

33 (65)

0.663

Genotype, n (%)

PKD1 + truncation

127 (53)

100 (53)

27 (53)

 

PKD1 + no truncation

60 (25)

49 (26)

11 (22)

0.691

PKD2 + NMD

52 (22)

39 (21)

13 (25)

 

htTKV*, ml/m

Mean (± sd)

621.6 ± 373.9

606.6 ± 367.7

683.7 ± 403.5

0.222

Median (IQR)

504.4 (350.2, 773.9)

479.9 (342.4, 726.9)

567.5 (382.6, 872.7)

Iothalamate Clearance*ϕ, ml/min/1.73m2

Mean (± sd)

97.7 ± 24.8

98.2 ± 24.6

96.9 ± 25.2

0.358

Median (IQR)

94.70 (78.78, 114.75)

96.36 (78.74, 114.72)

88.71 (79.05, 114.83)

  1. Values are given for the total population and based on caffeine intake. *P-value based on Wilcoxon rank sum test due to violation of t-test assumptions. ϕN = 234 (5 values missing at baseline but contributed subsequent measures for mixed model results). NMD refers to no mutation detected in the genetic analysis